A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme
Location(s): United States
Primary Outcome Measures:
Characterize the safety and tolerability of SL-701
Estimate the percent of patients alive 12 months after the initiation of SL-701 (OS-12
Estimate the objective response rate (ORR)
Secondary Outcome Measures:
Estimate duration of response
Estimate the percent of patients alive and progression-free survival at 6 months (PFS-6) after the initiation of SL-701.
Estimate the distributions of progression-free survival (PFS) and overall survival (OS).
Estimated Enrollment: 76
Study Start Date: May 2014
Estimated Study Completion Date: April 2017
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)